A single-line order from the US Supreme Court has scotched hopes on the part of Vanda Pharmaceuticals (Nasdaq: VNDA) of resurrecting patents for Hetlioz (tasime 23 April 2024
Long-term partners BioArctic and Eisai have announced a new research agreement regarding BAN2802, a potential treatment combining the former company’s proprieta 23 April 2024
Connecticut, USA-based biotech company Biohaven has priced an underwritten public offering with the goal of raising approximately $230 million. 19 April 2024
Novartis has announced data from the ALITHIOS open-label extension study showing sustained efficacy of first-line, continuous Kesimpta (ofatumumab) treatment fo 17 April 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.